8-K
false0001672619CO 0001672619 2022-12-31 0001672619 2021-12-31 0001672619 2022-01-01 2022-12-31 0001672619 2021-01-01 2021-12-31 0001672619 2023-06-23 2023-06-23 0001672619 2020-06-30 0001672619 2020-06-01 2020-06-30 0001672619 2023-02-23 2023-02-23 0001672619 2021-02-28 0001672619 2021-03-01 0001672619 2022-01-31 0001672619 2021-03-01 2021-03-31 0001672619 2022-01-01 2022-01-31 0001672619 2022-04-01 2022-04-30 0001672619 2023-02-23 0001672619 2020-01-01 2020-12-31 0001672619 2020-12-31 0001672619 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0001672619 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0001672619 us-gaap:ConvertiblePreferredStockMember 2022-01-01 2022-12-31 0001672619 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001672619 elvn:UnvestedRestrictedStockMember 2022-01-01 2022-12-31 0001672619 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2022-01-01 2022-12-31 0001672619 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2022-01-01 2022-12-31 0001672619 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001672619 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001672619 us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0001672619 elvn:SeriesSeedConvertiblePreferredStockMember 2022-01-01 2022-12-31 0001672619 elvn:SeriesAConvertiblePreferredStockMember 2022-01-01 2022-12-31 0001672619 elvn:SeriesBConvertiblePreferredStockMember 2022-01-01 2022-12-31 0001672619 elvn:LaboratoryEquipmentMember 2022-01-01 2022-12-31 0001672619 us-gaap:ComputerEquipmentMember 2022-01-01 2022-12-31 0001672619 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001672619 us-gaap:ConvertiblePreferredStockMember 2022-01-01 2022-12-31 0001672619 srt:MinimumMember us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0001672619 srt:MaximumMember us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0001672619 srt:MaximumMember 2022-01-01 2022-12-31 0001672619 srt:MinimumMember 2022-01-01 2022-12-31 0001672619 us-gaap:DividendPaidMember 2022-01-01 2022-12-31 0001672619 us-gaap:DividendDeclaredMember 2022-01-01 2022-12-31 0001672619 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001672619 us-gaap:AccountsPayableMember 2022-01-01 2022-12-31 0001672619 us-gaap:AccruedLiabilitiesMember 2022-01-01 2022-12-31 0001672619 us-gaap:StateAndLocalJurisdictionMember us-gaap:CaliforniaFranchiseTaxBoardMember elvn:TaxYearTwoThousandAndThirtyNineMember 2022-01-01 2022-12-31 0001672619 us-gaap:StateAndLocalJurisdictionMember elvn:ColoradoTaxAuthorityMember elvn:TaxYearTwoThousandFortyOneMember 2022-01-01 2022-12-31 0001672619 elvn:TwoThousandAndNineteenEquityIncentivePlanMember 2022-01-01 2022-12-31 0001672619 us-gaap:StateAndLocalJurisdictionMember us-gaap:InternalRevenueServiceIRSMember elvn:TaxYearTwoThousandFortyOneMember us-gaap:ResearchMember 2022-01-01 2022-12-31 0001672619 us-gaap:ResearchMember 2022-01-01 2022-12-31 0001672619 elvn:TheTaxCutsAndJobsActMember elvn:PostTaxYearTwoThousandAndTwentyOneMember 2022-01-01 2022-12-31 0001672619 elvn:TaxYearTwoThousandTwentyOneAndPriorMember 2022-01-01 2022-12-31 0001672619 us-gaap:ConvertiblePreferredStockMember 2022-12-31 0001672619 elvn:LaboratoryEquipmentMember 2022-12-31 0001672619 us-gaap:ComputerEquipmentMember 2022-12-31 0001672619 elvn:SeriesSeedConvertiblePreferredStockMember 2022-12-31 0001672619 elvn:SeriesAConvertiblePreferredStockMember 2022-12-31 0001672619 elvn:SeriesBConvertiblePreferredStockMember 2022-12-31 0001672619 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2022-12-31 0001672619 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2022-12-31 0001672619 us-gaap:ConvertiblePreferredStockMember elvn:MergerAgreementMember 2022-12-31 0001672619 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0001672619 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0001672619 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0001672619 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0001672619 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001672619 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001672619 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001672619 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001672619 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:IPOMember 2022-12-31 0001672619 us-gaap:OtherNoncurrentLiabilitiesMember 2022-12-31 0001672619 us-gaap:RestrictedStockMember 2022-12-31 0001672619 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember elvn:NotExpirableMember 2022-12-31 0001672619 us-gaap:StateAndLocalJurisdictionMember us-gaap:CaliforniaFranchiseTaxBoardMember elvn:TaxYearTwoThousandAndThirtyNineMember 2022-12-31 0001672619 us-gaap:StateAndLocalJurisdictionMember elvn:ColoradoTaxAuthorityMember elvn:TaxYearTwoThousandFortyOneMember 2022-12-31 0001672619 srt:MinimumMember 2022-12-31 0001672619 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember elvn:TaxYearTwoThousandFortyOneMember us-gaap:ResearchMember 2022-12-31 0001672619 us-gaap:StateAndLocalJurisdictionMember us-gaap:CaliforniaFranchiseTaxBoardMember elvn:NotExpirableMember us-gaap:ResearchMember 2022-12-31 0001672619 us-gaap:ResearchMember 2022-12-31 0001672619 us-gaap:ConvertiblePreferredStockMember 2021-12-31 0001672619 elvn:LaboratoryEquipmentMember 2021-12-31 0001672619 us-gaap:ComputerEquipmentMember 2021-12-31 0001672619 elvn:SeriesSeedConvertiblePreferredStockMember 2021-12-31 0001672619 elvn:SeriesAConvertiblePreferredStockMember 2021-12-31 0001672619 elvn:SeriesBConvertiblePreferredStockMember 2021-12-31 0001672619 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2021-12-31 0001672619 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2021-12-31 0001672619 us-gaap:ConvertiblePreferredStockMember elvn:MergerAgreementMember 2021-12-31 0001672619 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0001672619 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0001672619 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0001672619 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0001672619 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001672619 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001672619 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001672619 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001672619 us-gaap:OtherNoncurrentLiabilitiesMember 2021-12-31 0001672619 us-gaap:RestrictedStockMember 2021-12-31 0001672619 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001672619 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001672619 us-gaap:ConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001672619 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001672619 elvn:UnvestedRestrictedStockMember 2021-01-01 2021-12-31 0001672619 us-gaap:AccountsPayableMember 2021-01-01 2021-12-31 0001672619 us-gaap:AccruedLiabilitiesMember 2021-01-01 2021-12-31 0001672619 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001672619 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001672619 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2021-01-01 2021-12-31 0001672619 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2021-01-01 2021-12-31 0001672619 us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001672619 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001672619 elvn:SeriesSeedConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001672619 elvn:SeriesAConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001672619 elvn:SeriesBConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001672619 us-gaap:ConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001672619 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001672619 us-gaap:ResearchMember 2021-01-01 2021-12-31 0001672619 srt:MaximumMember elvn:EnlivenIncMember elvn:TwoThousandAndNineteenEquityIncentivePlanMember 2019-07-31 0001672619 elvn:TwoThousandAndNineteenEquityIncentivePlanMember elvn:EnlivenIncMember 2020-04-30 0001672619 elvn:TwoThousandAndNineteenEquityIncentivePlanMember elvn:EnlivenIncMember 2020-04-01 2020-04-30 0001672619 elvn:TwoThousandAndNineteenEquityIncentivePlanMember elvn:EnlivenIncMember 2020-12-31 0001672619 elvn:TwoThousandAndNineteenEquityIncentivePlanMember elvn:EnlivenIncMember 2020-12-01 2020-12-31 0001672619 elvn:TwoThousandAndNineteenEquityIncentivePlanMember 2020-08-01 2020-08-31 0001672619 elvn:TwoThousandAndNineteenEquityIncentivePlanMember 2020-08-31 0001672619 elvn:StockOptionRepricingMember 2022-08-09 2022-08-09 0001672619 elvn:StockOptionRepricingMember elvn:TwoThousandAndNineteenEquityIncentivePlanMember 2022-08-09 2022-08-09 0001672619 elvn:EnlivenIncMember us-gaap:RestrictedStockMember 2019-06-01 2019-06-30 0001672619 us-gaap:RestrictedStockMember elvn:EnlivenIncMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2019-06-01 2019-06-30 0001672619 srt:MinimumMember us-gaap:RestrictedStockMember elvn:EnlivenIncMember 2019-06-01 2019-06-30 0001672619 srt:MaximumMember us-gaap:RestrictedStockMember elvn:EnlivenIncMember 2019-06-01 2019-06-30 0001672619 elvn:EmployeesAndConsultantsMember us-gaap:RestrictedStockMember elvn:EnlivenIncMember 2019-06-01 2020-12-31 0001672619 us-gaap:PreferredStockMember us-gaap:ConvertiblePreferredStockMember 2022-12-31 0001672619 us-gaap:CommonStockMember 2022-12-31 0001672619 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001672619 us-gaap:RetainedEarningsMember 2022-12-31 0001672619 us-gaap:PreferredStockMember us-gaap:ConvertiblePreferredStockMember 2020-12-31 0001672619 us-gaap:CommonStockMember 2020-12-31 0001672619 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001672619 us-gaap:RetainedEarningsMember 2020-12-31 0001672619 us-gaap:RestrictedStockMember 2020-12-31 0001672619 us-gaap:PreferredStockMember us-gaap:ConvertiblePreferredStockMember 2021-12-31 0001672619 us-gaap:CommonStockMember 2021-12-31 0001672619 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001672619 us-gaap:RetainedEarningsMember 2021-12-31 iso4217:USD utr:sqft xbrli:shares utr:Year xbrli:pure utr:Month iso4217:USD xbrli:shares elvn:DIRECTOR elvn:Segment elvn:Vote
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM
8-K
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 23, 2023
 
 
Enliven Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
 
 
 
Delaware
  
001-39247
  
81-1523849
(State or other jurisdiction
of incorporation)
  
(Commission
File Number)
  
(IRS Employer
Identification No.)
 
6200 Lookout Road
    
Boulder, CO
  
80301
(Address of principal executive offices)
  
(Zip Code)
(720)
647-8519
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
 
 
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
 
☐
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
 
☐
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
  
Trading
Symbol
  
Name of each exchange
on which registered
Common Stock, par value $0.001 per share
  
ELVN
  
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company  
☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  
☐
 
 
 
 
Item 5.07
Submission of Matters to a Vote of Security Holders.
Enliven Therapeutics, Inc. (the “
Company
”) held its Annual Meeting of stockholders (the “
Annual Meeting
”) on June 23, 2023. The matters voted upon at the Annual Meeting and the voting results for each proposal are set forth below.
Proposal 1: Election of two Class III Directors
 
Name of Director
   
For
     
Withheld
     
Broker Non-Votes
Richard Heyman, Ph.D.
   
 
30,518,067
 
   
 
385,508
 
   
1,641,388
Samuel Kintz, M.B.A.
   
 
30,900,278
 
   
 
3,297
 
   
1,641,388

Each director nominee was duly elected to serve until the 2026 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal.
Proposal 2: Ratification of the Appointment of Independent Registered Public Accounting Firm
 
For
  
Against
  
Abstain
32,543,338
  
1,460
  
165
The stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
 
Item 8.01
Other Events.
As previously reported, on February 23, 2023, the Company effected a
1-for-4
reverse stock split of its common stock (the “
Reverse Stock Split
”) in connection with its merger with Enliven Inc. (formerly, Enliven Therapeutics, Inc.) (“
Former Enliven
”). In connection with such merger, the Company issued common stock to Former Enliven stockholders based on an exchange ratio of approximately 0.2951 shares of common stock for each share of Former Enliven capital stock (which exchange ratio reflects the Reverse Stock Split) (the “
Exchange Ratio
”). To reflect the Reverse Stock Split and the Exchange Ratio, the audited financial statements of Former Enliven as of December 31, 2022 and 2021 and for the years then ended have been recasted and are filed herewith as Exhibit 99.1. There have been no other changes to such financial statements.
The unaudited pro forma financial information of the Company as of March 31, 2023 and for the year ended December 31, 2022 and three-month period ended March 31, 2023 are filed herewith as Exhibit 99.2.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits
 
Exhibit
Number
   
Exhibit Description
23.1
   
99.1
   
99.2
   
104
   
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
ENLIVEN THERAPEUTICS, INC.
   
By:
  
/s/ Samuel Kintz
   
Samuel Kintz
   
President and Chief Executive Officer
Date: June 23, 2023